Ancora Heart's AccuCinch® Ventricular Restoration System device is designed to restore the structure and function of the enlarged left ventricle of the heart, thereby addressing the fundamental issue in the progression of heart failure in patients with reduced ejection fraction (HFrEF). The AccuCinch System is an investigational device, which is currently being studied in the CORCINCH-HF pivotal trial, a prospective, randomized, open-label, multicenter, international, clinical safety and efficacy investigation.
Ancora Heart and egnite, Inc. Announce Strategic Partnership to Accelerate Clinical Trial Enrollment for Heart Failure Patients
Mark Miles, chief commercial officer of Ancora Heart. “This partnership with egnite and The Christ Health Network will allow us to deploy AI tools such as egnite’s Trial Accelerator and expedite identification of eligible candidates for the CORCINCH-HF trial.”